Zydus Lifesciences Share Price Gains 1%; Gets Chinese Regulator’s Approval for Generic Anxiety Drug

Zydus Lifesciences Ltd has secured approval from China’s National Medical Products Administration (NMPA) to market Venlafaxine extended-release capsules in 75 mg and 150 mg strengths. 

This marks the company’s first regulatory approval in China, signalling a strategic expansion into the country’s growing pharmaceutical market for mental health treatments.

Regulatory Approval and Product Details

According to a company statement issued on Tuesday, Zydus Lifesciences received the NMPA’s approval to commercialise Venlafaxine ER capsules, a medication prescribed for major depressive disorder, generalised anxiety disorder, social anxiety disorder, and panic disorder.

Venlafaxine helps balance serotonin and norepinephrine levels in the brain, aiding mood stabilisation and anxiety reduction. With this approval, Zydus will be able to market the drug in China, enabling broader access to affordable treatment options for mental health conditions.

Strategic Significance

This marks Zydus Lifesciences’ first-ever approval from the Chinese health regulator. The milestone is seen as an important step in the company’s international growth strategy, particularly in the Asia-Pacific region, where demand for psychiatric and neurological medications is rising steadily.

The approval also reflects the company’s continued focus on diversifying its global portfolio and expanding into regulated international markets beyond the United States and Europe.

Zydus Lifesciences Share Price Performance

Zydus Lifesciences shares were trading at ₹948.15, up ₹9.25 or 0.99% from the previous close of ₹938.90 on the NSE.

The stock opened at ₹940.10, touched a high of ₹949.55, and recorded a low of ₹940.00 during early trade.

Read More: IFC Invests ₹285 Crore in Axis Max Life to Support Growth and Insurance Penetration in India.

Conclusion

The development is expected to enhance the company’s international presence and contribute to its long-term growth strategy in the pharmaceutical sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.